You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Invion Limited (IVX, formerly CBIO Limited) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has two key development programs: INV102 for inflammatory respiratory disease, and Chaperonin10 (CPN10) for the treatment of lupus. IVX also exploits the patented use of beta-2 adrenergic inverse agonism for the development of treatments for inflammatory conditions of the lungs such as asthma, chronic bronchitis and cystic fibrosis.
The Age 23/05/2013 |
The local sharemarket closed lower for a second consecutive day, dragged down by the banks and a surprisingly poor consumer sentiment report.
The Age 23/05/2013 |
Non-bank lender Resimac has made a bid to acquire the remnants of mortgage firm RAMS in a joint proposal with former Babcock & Brown banker Trevor Loewensohn.
The Age 23/05/2013 |
Department store Myer will switch its focus from relentless cost-cutting to driving sales growth and grabbing a greater slice of the discretionary spend by shoppers.
The Age 23/05/2013 |
Australia's top commodities agency has detailed a year of woe for the local resources industry and joined the Reserve Bank in declaring the peak of investment in the sector.
The Age 23/05/2013 |
Significant job losses are expected at Telstra after the telco announced sweeping changes to its operational structure as it shifts away from its legacy business.
Already a member? 
